ALKEM LABORATORIES | WOCKHARDT | ALKEM LABORATORIES/ WOCKHARDT |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 24.5 | -88.9 | - | View Chart |
P/BV | x | 5.9 | 2.0 | 300.2% | View Chart |
Dividend Yield | % | 0.8 | 0.0 | 41,887.6% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-20 |
WOCKHARDT Mar-18 |
ALKEM LABORATORIES/ WOCKHARDT |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,720 | 1,012 | 268.8% | |
Low | Rs | 1,660 | 532 | 312.4% | |
Sales per share (Unadj.) | Rs | 697.9 | 355.9 | 196.1% | |
Earnings per share (Unadj.) | Rs | 96.1 | -60.3 | -159.5% | |
Cash flow per share (Unadj.) | Rs | 117.3 | -46.8 | -250.8% | |
Dividends per share (Unadj.) | Rs | 25.00 | 0.01 | 250,000.0% | |
Dividend yield (eoy) | % | 1.1 | 0 | 88,092.3% | |
Book value per share (Unadj.) | Rs | 515.2 | 257.8 | 199.9% | |
Shares outstanding (eoy) | m | 119.57 | 110.63 | 108.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.1 | 2.2 | 144.7% | |
Avg P/E ratio | x | 22.8 | -12.8 | -178.0% | |
P/CF ratio (eoy) | x | 18.7 | -16.5 | -113.2% | |
Price / Book Value ratio | x | 4.3 | 3.0 | 142.0% | |
Dividend payout | % | 26.0 | 0 | -156,776.3% | |
Avg Mkt Cap | Rs m | 261,879 | 85,379 | 306.7% | |
No. of employees | `000 | 14.3 | 6.3 | 229.1% | |
Total wages/salary | Rs m | 15,055 | 9,371 | 160.7% | |
Avg. sales/employee | Rs Th | 5,822.6 | 6,295.0 | 92.5% | |
Avg. wages/employee | Rs Th | 1,050.5 | 1,498.3 | 70.1% | |
Avg. net profit/employee | Rs Th | 802.0 | -1,066.3 | -75.2% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 83,444 | 39,369 | 212.0% | |
Other income | Rs m | 1,042 | 1,202 | 86.7% | |
Total revenues | Rs m | 84,486 | 40,571 | 208.2% | |
Gross profit | Rs m | 14,734 | 18 | 80,513.1% | |
Depreciation | Rs m | 2,528 | 1,495 | 169.0% | |
Interest | Rs m | 651 | 2,555 | 25.5% | |
Profit before tax | Rs m | 12,598 | -2,830 | -445.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -3,582 | 0.0% | |
Tax | Rs m | 1,105 | 257 | 429.9% | |
Profit after tax | Rs m | 11,493 | -6,669 | -172.3% | |
Gross profit margin | % | 17.7 | 0 | 37,986.4% | |
Effective tax rate | % | 8.8 | -9.1 | -96.6% | |
Net profit margin | % | 13.8 | -16.9 | -81.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 54,960 | 33,796 | 162.6% | |
Current liabilities | Rs m | 32,433 | 26,917 | 120.5% | |
Net working cap to sales | % | 27.0 | 17.5 | 154.5% | |
Current ratio | x | 1.7 | 1.3 | 135.0% | |
Inventory Days | Days | 80 | 79 | 100.3% | |
Debtors Days | Days | 72 | 89 | 80.9% | |
Net fixed assets | Rs m | 32,710 | 39,664 | 82.5% | |
Share capital | Rs m | 239 | 553 | 43.2% | |
"Free" reserves | Rs m | 61,368 | 27,968 | 219.4% | |
Net worth | Rs m | 61,607 | 28,522 | 216.0% | |
Long term debt | Rs m | 1,592 | 21,731 | 7.3% | |
Total assets | Rs m | 99,433 | 81,620 | 121.8% | |
Interest coverage | x | 20.4 | -0.1 | -18,939.5% | |
Debt to equity ratio | x | 0 | 0.8 | 3.4% | |
Sales to assets ratio | x | 0.8 | 0.5 | 174.0% | |
Return on assets | % | 12.2 | -5.0 | -242.3% | |
Return on equity | % | 18.7 | -23.4 | -79.8% | |
Return on capital | % | 21.0 | -7.7 | -273.2% | |
Exports to sales | % | 19.1 | 0 | - | |
Imports to sales | % | 3.0 | 0 | - | |
Exports (fob) | Rs m | 15,917 | NA | - | |
Imports (cif) | Rs m | 2,483 | NA | - | |
Fx inflow | Rs m | 16,061 | 9,807 | 163.8% | |
Fx outflow | Rs m | 2,483 | 1,789 | 138.8% | |
Net fx | Rs m | 13,578 | 8,019 | 169.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 5,851 | 684 | 854.9% | |
From Investments | Rs m | -7,414 | 6,302 | -117.6% | |
From Financial Activity | Rs m | 792 | -7,695 | -10.3% | |
Net Cashflow | Rs m | -731 | -664 | 110.1% |
Indian Promoters | % | 66.9 | 74.5 | 89.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 33.1 | 2.3 | 1,439.1% | |
FIIs | % | 0.0 | 7.7 | - | |
ADR/GDR | % | 0.0 | 0.1 | - | |
Free float | % | 0.0 | 15.4 | - | |
Shareholders | 68,381 | 67,757 | 100.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALKEM LABORATORIES With: CIPLA PIRAMAL ENTERPRISES NATCO PHARMA SHASUN PHARMA PFIZER
Compare ALKEM LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
ASTRAZENECA PHARMA share price is trading down by 5% and its current market price is Rs 4,200. The BSE HEALTHCARE is down by 2.5%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 1.2%) and IPCA LABS (up 1.0%). The top losers are ASTRAZENECA PHARMA (down 5.3%) and WOCKHARDT (down 5.2%).
For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.
For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More